Les thérapies géniques en neurologie

Vgontzas, 2019, Introduction to neurogenetics, Am J Med, 132, 142, 10.1016/j.amjmed.2018.07.041 Swinnen, 2019, RNA toxicity in non-coding repeat expansion disorders, EMBO J, e101112 Brunet de Courssou, 2023, Les thérapies antisens en neurologie, Prat Neurol – FMC 2021 Blaese, 1995, T lymphocyte-directed gene therapy for ADA − SCID: initial trial results after 4 years, Science, 270, 475, 10.1126/science.270.5235.475 Raper, 2003, Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol Genet Metab, 80, 148, 10.1016/j.ymgme.2003.08.016 Hacein-Bey-Abina, 2003, LMO2-Associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science, 302, 415, 10.1126/science.1088547 Gaudet, 2013, Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial, Gene Ther, 20, 361, 10.1038/gt.2012.43 Kaeppel, 2013, A largely random AAV integration profile after LPLD gene therapy, Nat Med, 19, 889, 10.1038/nm.3230 Cicalese, 2016, Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency, Blood, 128, 45, 10.1182/blood-2016-01-688226 Day, 2021, Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial, Lancet Neurol, 20, 284, 10.1016/S1474-4422(21)00001-6 Mercuri, 2021, Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial, Lancet Neurol, 20, 832, 10.1016/S1474-4422(21)00251-9 Fumagalli, 2022, Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access, Lancet, 399, 372, 10.1016/S0140-6736(21)02017-1 Eichler, 2017, Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy, N Engl J Med, 377, 1630, 10.1056/NEJMoa1700554 Li, 2022, The role of brain derived neurotrophic factor in central nervous system, Front Aging Neurosci, 14, 986443, 10.3389/fnagi.2022.986443 Arora, 2022, Functionalized nanoparticles for brain targeted BDNF gene therapy to rescue Alzheimer's disease pathology in transgenic mouse model, Int J Biol Macromol, 208, 901, 10.1016/j.ijbiomac.2022.03.203 Nagahara, 2018, MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates, Gene Ther, 25, 104, 10.1038/s41434-018-0010-2 Nieuwenhuis, 2021, Optimization of adeno-associated viral vector-mediated transduction of the corticospinal tract: comparison of four promoters, Gene Ther, 28, 56, 10.1038/s41434-020-0169-1 Johnson, 2022, Bioinformatic design of dendritic cell-specific synthetic promoters, ACS Synth Biol, 11, 1613, 10.1021/acssynbio.2c00027 Jüttner, 2019, Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans, Nat Neurosci, 22, 1345, 10.1038/s41593-019-0431-2 Eriksson, 2022, Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy, Front Med, 9, 1052318, 10.3389/fmed.2022.1052318 Zhong, 2020, A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo, Nat Biotechnol, 38, 169, 10.1038/s41587-019-0357-y Crosby, 2017, Transgene expression and host cell responses to replication-defective, single-cycle, and replication-competent adenovirus vectors, Genes, 8, 79, 10.3390/genes8020079 Bulcha, 2021, Viral vector platforms within the gene therapy landscape, Signal Transduct Target Ther, 6, 53, 10.1038/s41392-021-00487-6 Manno, 2006, Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nat Med, 12, 342, 10.1038/nm1358 Sehara, 2017, Persistent expression of dopamine-synthesizing enzymes 15 years after gene transfer in a primate model of Parkinson's disease, Hum Gene Ther Clin Dev, 28, 74, 10.1089/humc.2017.010 Papayannakos, 2013, Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy, Gene Ther, 20, 581, 10.1038/gt.2012.88 Urnov, 2010, Genome editing with engineered zinc finger nucleases, Nat Rev Genet, 11, 636, 10.1038/nrg2842 Joung, 2013, TALENs: a widely applicable technology for targeted genome editing, Nat Rev Mol Cell Biol, 14, 49, 10.1038/nrm3486 Makarova, 2020, Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants, Nat Rev Microbiol, 18, 67, 10.1038/s41579-019-0299-x Allen, 2021, Using synthetically engineered guide RNAs to enhance CRISPR genome editing systems in mammalian cells, Front Genome Ed, 2, 617910, 10.3389/fgeed.2020.617910 Kleinstiver, 2015, Engineered CRISPR-Cas9 nucleases with altered PAM specificities, Nature, 523, 481, 10.1038/nature14592 Slaymaker, 2016, Rationally engineered Cas9 nucleases with improved specificity, Science, 351, 84, 10.1126/science.aad5227 Kleinstiver, 2016, High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects, Nature, 529, 490, 10.1038/nature16526 Saifaldeen, 2020, CRISPR FokI dead Cas9 system: principles and applications in genome engineering, Cells, 9, 2518, 10.3390/cells9112518 Yang, 2020, Methods favoring homology-directed repair choice in response to CRISPR/Cas9 induced-double strand breaks, Int J Mol Sci, 21, 6461, 10.3390/ijms21186461 Paulsen, 2017, Ectopic expression of RAD52 and dn53BP1 improves homology-directed repair during CRISPR–Cas9 genome editing, Nat Biomed Eng, 1, 878, 10.1038/s41551-017-0145-2 Jayavaradhan, 2019, CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites, Nat Commun, 10, 2866, 10.1038/s41467-019-10735-7 Wang, 2022, dCas9-based gene editing for cleavage-free genomic knock-in of long sequences, Nat Cell Biol, 24, 268, 10.1038/s41556-021-00836-1 Nishida, 2016, Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems, Science, 353, aaf8729, 10.1126/science.aaf8729 Gaudelli, 2017, Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage, Nature, 551, 464, 10.1038/nature24644 Newby, 2021, In vivo somatic cell base editing and prime editing, Mol Ther, 29, 3107, 10.1016/j.ymthe.2021.09.002 Verve therapeutics doses first human with an investigational in vivo base editing medicine, VERVE-101, as a potential treatment for heterozygous familial hypercholesterolemia | Verve Therapeutics n.d. https://ir.vervetx.com/news-releases/news-release-details/verve-therapeutics-doses-first-human-investigational-vivo-base/ [accessed July 28, 2022]. Mahfoudhi, 2015, Propriétés et rôles biologiques des protéines TET au cours du développement et de l’hématopoïèse, Med Sci, 31, 268 Sung, 2020, CRISPR-mediated promoter de/methylation technologies for gene regulation, Arch Pharm Res, 43, 705, 10.1007/s12272-020-01257-8 Goell, 2021, CRISPR/Cas-based epigenome editing: advances, applications, and clinical utility, Trends Biotechnol, 39, 678, 10.1016/j.tibtech.2020.10.012 Bönnemann, 2023, Dystrophin immunity after gene therapy for Duchenne's muscular dystrophy, N Engl J Med, 388, 2294, 10.1056/NEJMc2212912 Philippidis, 2021, Fourth boy dies in clinical trial of Astellas’ AT132, Hum Gene Ther, 32, 1008, 10.1089/hum.2021.29182.bfs Ertl, 2022, Immunogenicity and toxicity of AAV gene therapy, Front Immunol, 13, 975803, 10.3389/fimmu.2022.975803 Calcedo, 2009, Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses, J Infect Dis, 199, 381, 10.1086/595830 Boutin, 2010, Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors, Hum Gene Ther, 21, 704, 10.1089/hum.2009.182 George, 2020, Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B, Mol Ther, 28, 2073, 10.1016/j.ymthe.2020.06.001 Prasad, 2022, Immune responses and immunosuppressive strategies for adeno-associated virus-based gene therapy for treatment of central nervous system disorders: current knowledge and approaches, Hum Gene Ther, 33, 1228, 10.1089/hum.2022.138 Chu, 2021, Immunomodulation in administration of rAAV: preclinical and clinical adjuvant pharmacotherapies, Front Immunol, 12, 658038, 10.3389/fimmu.2021.658038 Tang, 2023, Immunosuppression reduces rAAV2.5T neutralizing antibodies that limit efficacy following repeat dosing to ferret lungs, Mol Ther - Methods Clin Dev, 29, 70, 10.1016/j.omtm.2023.02.015 Earley, 2023, Evading and overcoming AAV neutralization in gene therapy, Trends Biotechnol, 41, 836, 10.1016/j.tibtech.2022.11.006 Adams, 2018, Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis, N Engl J Med, 379, 11, 10.1056/NEJMoa1716153 Furtado, 2018, Overcoming the blood-brain barrier: the role of nanomaterials in treating neurological diseases, Adv Mater, 30, 1801362, 10.1002/adma.201801362 Zou, 2020, Single siRNA nanocapsules for effective siRNA brain delivery and glioblastoma treatment. Adv Mater, 32, 2000416 Yonezawa, 2020, Recent advances in siRNA delivery mediated by lipid-based nanoparticles, Adv Drug Deliv Rev, 154–155, 64, 10.1016/j.addr.2020.07.022 Zhou, 2022, Routes of administration for adeno-associated viruses carrying gene therapies for brain diseases, Front Mol Neurosci, 15, 988914, 10.3389/fnmol.2022.988914 Piguet, 2021, The challenge of gene therapy for neurological diseases: strategies and tools to achieve efficient delivery to the central nervous system, Hum Gene Ther, 32, 349, 10.1089/hum.2020.105 Audouard, 2021, Complete correction of brain and spinal cord pathology in metachromatic leukodystrophy mice, Front Mol Neurosci, 14, 677895, 10.3389/fnmol.2021.677895 Liguore, 2019, AAV-PHP.B. administration results in a differential pattern of CNS biodistribution in non-human primates compared with mice, Mol Ther, 27, 2018, 10.1016/j.ymthe.2019.07.017 Kay, 2020, Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy, Genet Med, 22, 1296, 10.1038/s41436-020-0824-3 Wirth, 2020, Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next, Annu Rev Genomics Hum Genet, 21, 231, 10.1146/annurev-genom-102319-103602 Ramdas, 2020, New treatments in spinal muscular atrophy: an overview of currently available data, Expert Opin Pharmacother, 21, 307, 10.1080/14656566.2019.1704732 Pattali, 2019, AAV9 Vector: a novel modality in gene therapy for spinal muscular atrophy, Gene Ther, 26, 287, 10.1038/s41434-019-0085-4 Mendell, 2017, Single-dose gene-replacement therapy for spinal muscular atrophy, N Engl J Med, 377, 1713, 10.1056/NEJMoa1706198 Mendell, 2021, Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy, JAMA Neurol, 78, 834, 10.1001/jamaneurol.2021.1272 Lowes, 2019, Impact of age and motor function in a phase 1/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy, Pediatr Neurol, 98, 39, 10.1016/j.pediatrneurol.2019.05.005 Viscidi, 2021, The incidence of hydrocephalus among patients with and without spinal muscular atrophy (SMA): results from a US electronic health records study, Orphanet J Rare Dis, 16, 207, 10.1186/s13023-021-01822-4 Colella, 2018, Emerging issues in AAV-mediated in vivo gene therapy, Mol Ther - Methods Clin Dev, 8, 87, 10.1016/j.omtm.2017.11.007 Chand, 2021, Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy, J Hepatol, 74, 560, 10.1016/j.jhep.2020.11.001 Finkel, 2023, Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase I ascending-dose study (STRONG), J Neuromuscul Dis, 10, 389, 10.3233/JND-221560 Chand, 2021, Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series, J Pediatr, 231, 265, 10.1016/j.jpeds.2020.11.054 Guillou, 2022, Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy, Blood Adv, 6, 4266, 10.1182/bloodadvances.2021006419 Yazaki, 2022, Child neurology: pathologically confirmed thrombotic microangiopathy caused by onasemnogene abeparvovec treatment for SMA, Neurology, 98, 808, 10.1212/WNL.0000000000200676 Wijngaarde, 2020, Abnormal coagulation parameters are a common non-neuromuscular feature in patients with spinal muscular atrophy, J Neurol Neurosurg Psychiatry, 91, 212, 10.1136/jnnp-2019-321506 Solid biosciences announces clinical hold On SGT-001 phase I/II clinical trial for Duchenne muscular dystrophy. Solid Biosci n.d. https://www.solidbio.com/about/media/press-releases/solid-biosciences-announces-clinical-hold-on-sgt-001-phase-i-ii-clinical-trial-for-duchenne-muscular-dystrophy [accessed April 17, 2022]. Lagrue, 2021, Micro/mini-dystrophines et dystrophie musculaire de Duchenne : entre espoirs et défis, Cah Myol, 23, 12, 10.1051/myolog/202123004 Pfizer's new phase 1b results of gene therapy in ambulatory boys with Duchenne muscular dystrophy (DMD) support advancement into pivotal phase 3 study | Pfizer n.d. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-new-phase-1b-results-gene-therapy-ambulatory-boys [accessed April 14, 2022]. Pfizer to open first US sites in phase 3 trial of investigational gene therapy for ambulatory patients with Duchenne muscular dystrophy | Pfizer n.d. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-open-first-us-sites-phase-3-trial-investigational [accessed May 24, 2022]. Mendell, 2020, Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial, JAMA Neurol, 77, 1122, 10.1001/jamaneurol.2020.1484 Chen, 2021, In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers, Genome Med, 13, 57, 10.1186/s13073-021-00876-0 Chemello, 2021, Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing, Sci Adv, 7, eabg4910, 10.1126/sciadv.abg4910 Xu, 2021, Efficient precise in vivo base editing in adult dystrophic mice, Nat Commun, 12, 3719, 10.1038/s41467-021-23996-y Zygmunt, 2019, rAAVrh74.MCK.GALGT2 demonstrates safety and widespread muscle glycosylation after intravenous delivery in C57BL/6J mice, Mol Ther Methods Clin Dev, 15, 305, 10.1016/j.omtm.2019.10.005 Rowczenio, 2014, Online registry for mutations in hereditary amyloidosis including nomenclature recommendations, Hum Mutat, 35, E2403, 10.1002/humu.22619 Mariani, 2015, Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France, Ann Neurol, 78, 901, 10.1002/ana.24519 Lozeron, 2018, Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy, Neurology, 91, e143, 10.1212/WNL.0000000000005777 Gertz, 2019, Advances in the treatment of hereditary transthyretin amyloidosis: a review, Brain Behav, 9, e01371, 10.1002/brb3.1371 Adams, 2000, The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation, Brain J Neurol, 123, 1495, 10.1093/brain/123.7.1495 Adams, 2019, Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease, Nat Rev Neurol, 15, 387, 10.1038/s41582-019-0210-4 Algalarrondo, 2015, Prediction of long-term survival after liver transplantation for familial transthyretin amyloidosis, J Am Coll Cardiol, 66, 2154, 10.1016/j.jacc.2015.08.870 Algalarrondo, 2018, Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy, Amyloid Int J Exp Clin Investig, 25, 253 Yazaki, 2007, Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients, Am J Transplant, 7, 235, 10.1111/j.1600-6143.2006.01585.x Liepnieks, 2010, Progression of transthyretin amyloid neuropathy after liver transplantation, Neurology, 75, 324, 10.1212/WNL.0b013e3181ea15d4 Monteiro, 2019, Predictive model of response to tafamidis in hereditary ATTR polyneuropathy, JCI Insight, 4, e126526, 10.1172/jci.insight.126526 Adams, 2016, TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies, Expert Opin Pharmacother, 17, 791, 10.1517/14656566.2016.1145664 Gillmore, 2021, CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis, N Engl J Med, 385, 493, 10.1056/NEJMoa2107454 Finn, 2018, A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing, Cell Rep, 22, 2227, 10.1016/j.celrep.2018.02.014 Musunuru, 2021, In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates, Nature, 593, 429, 10.1038/s41586-021-03534-y 1993, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group, Cell, 72, 971, 10.1016/0092-8674(93)90585-E Lee, 2019, CAG repeat not polyglutamine length determines timing of Huntington’s disease onset, Cell, 178, 887, 10.1016/j.cell.2019.06.036 2022 2021 Kacher, 2022, Altered cholesterol homeostasis in Huntington's disease, Front Aging Neurosci, 14, 797220, 10.3389/fnagi.2022.797220 Boussicault, 2016, CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease, Brain, 139, 953, 10.1093/brain/awv384 Kacher, 2019, CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease, Brain, 142, 2432, 10.1093/brain/awz174 Sevin, 2021, Clinical trials for gene therapy in lysosomal diseases with CNS involvement, Front Mol Biosci, 8, 624988, 10.3389/fmolb.2021.624988 Ellison, 202346874, Advances in therapies for neurological lysosomal storage disorders, J Inherit Metab Dis Massaro, 2021, Gene therapy for lysosomal storage disorders: ongoing studies and clinical development, Biomolecules, 11, 611, 10.3390/biom11040611 Favret, 2020, Pre-clinical mouse models of neurodegenerative lysosomal storage diseases, Front Mol Biosci, 7, 57, 10.3389/fmolb.2020.00057 Tardieu, 2014, Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial, Hum Gene Ther, 25, 506, 10.1089/hum.2013.238 Lysogene. Lysogene provides clinical update on AAVance phase 2/3 clinical trial with gene therapy LYS-SAF302 for the treatment of MPS IIIA at the 25th Annual ASGCT Meeting – Lysogene n.d. https://www.lysogene.com/lysogene-provides-clinical-update-on-aavance-phase-2-3-clinical-trial-with-gene-therapy-lys-saf302-for-the-treatment-of-mps-iiia-at-the-25th-annual-asgct-meeting/ [accessed May 24, 2022]. Lysogene. Lysogene provides update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA – Lysogene n.d. https://www.lysogene.com/lysogene-provides-update-on-the-aavance-clinical-trial-evaluating-lys-saf302-in-patients-with-mps-iiia/ [accessed May 24, 2022]. Tardieu, 2017, Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial, Lancet Neurol, 16, 712, 10.1016/S1474-4422(17)30169-2 Deiva, 2021, Intracerebral gene therapy in four children with Sanfilippo B syndrome: 5.5-year follow-up results, Hum Gene Ther, 32, 1251, 10.1089/hum.2021.135 Gougeon, 2021, Cell-mediated immunity to NAGLU transgene following intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome, Front Immunol, 12, 655478, 10.3389/fimmu.2021.655478 Cearley, 2006, Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain, Mol Ther, 13, 528, 10.1016/j.ymthe.2005.11.015 Rosenberg, 2014, Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates, Hum Gene Ther Clin Dev, 25, 164, 10.1089/humc.2013.239 Sevin, 2018, Intracerebral gene therapy in children with metachromatic leukodystrophy: results of a phase I/II trial, Mol Genet Metab, 123, S129, 10.1016/j.ymgme.2017.12.352 Í Dali, 2020, Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: results from a phase 1/2 clinical trial, Mol Genet Metab, 131, 235, 10.1016/j.ymgme.2020.07.002 Sessa, 2016, Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial, Lancet, 388, 476, 10.1016/S0140-6736(16)30374-9 Biffi, 2013, Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy, Science, 341, 1233158, 10.1126/science.1233158 St. Martin, 2023433567, Single systemic administration of a gene therapy leading to disease treatment in metachromatic leukodystrophy Arsa knockout mice, J Neurosci Malone, 2019, Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients, J Mark Access Health Policy, 7, 1601484, 10.1080/20016689.2019.1601484